HoneyBear Biosciences, Inc is a Taiwan based biotech company with a vision for global pharmaceutical market. We strive to develop new antibody technologies to bring novel antibody-drug conjugates to the patients with devastating cancers. HoneyBear Biosciences exclusively licensed the trimannosyl glycan conjugation platform and ADC drug candidates from Development Center for Biotechnology. We are currently focusing on taking this strongly competitive site specific conjugation platform to the clinical stage. Our business strategy is to utilize this platform to develop and commercialize novel anti cancer medicines through licensing and partnership with biotech or pharmaceutical companies.